



Sinco Pharmaceuticals Holdings Limited
興科蓉醫藥控股有限公司

(Incorporated under the laws of Cayman Islands with limited liability)
(根據開曼群島法例註冊成立的有限公司)
(Stock Code 股份代號：6833)

NOTIFICATION LETTER 通知信函

25 April 2023

Dear Shareholders,

Sinco Pharmaceuticals Holdings Limited (the “Company”)
- Notice of Publication of 2022 Environmental, Social and Governance Report (“Current ESG report”)

The English and Chinese versions of the Company’s Current ESG report are available on the Company’s website at www.sinco-pharm.com and the HKEXnews website at www.hkexnews.hk. You may access the Current ESG report by clicking “Investor Relations” on the home page of our website, then selecting “2022 Environmental, Social and Governance Report” under “Announcements & Circulars” and viewing them using Adobe® Reader; or the HKEXnews website by clicking the relevant title as appeared thereon to view and/or download the Current ESG Report.

If you wish to receive the printed version of the Current ESG report, you may send your request in writing to the Company c/o the Company’s share registrar, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong.

Yours faithfully,
For and on behalf of
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

各位股東：

興科蓉醫藥控股有限公司（「本公司」）
- 2022年環境、社會及管治報告（「本次環境、社會及管治報告」）之發佈通知

本公司的本次環境、社會及管治報告中，英文版本已上載於本公司網站 www.sinco-pharm.com 及香港交易所披露易網站 www.hkexnews.hk，歡迎瀏覽。閣下可於本公司網站主頁按「投資者關係」一項，再在「公告及通函」項下選擇「2022年環境、社會及管治報告」並使用 Adobe® Reader 開啟或在香港交易所披露易網站透過點擊相關顯示的標題以閱覽及／或下載 2022 環境、社會及管治報告。

如 閣下希望收取本次環境、社會及管治報告的印刷本，閣下可將申請以書面方式通知本公司證券登記處香港中央證券登記有限公司以轉交本公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

代表
興科蓉醫藥控股有限公司
黃祥彬
主席兼執行董事
謹啟

2023 年 4 月 25 日